How the Bioleaching Process Actually Works for Mining Investors

#

Most mining investors meet the word “bioleaching” in a company report and file it away next to flotation and cyanidation, a processing step to skim over on the way to the recovery numbers. That instinct can be an expensive one.

The method a company chooses, and the ore type it applies that method to, can decide whether a project is genuinely viable or a marginal proposition that will never deliver its projected recovery rates.

Here is the first thing to understand: bioleaching is not one process. It is a family of methods united by a single principle. Bacteria do the chemical work of breaking open sulphide minerals that would otherwise demand high-temperature smelting or pressure oxidation.

That matters more now than it used to. A growing share of copper and gold deposits entering development are low-grade, sulphidic, or refractory, which makes conventional processing uneconomic for an increasing proportion of new projects.

After reading this, you will know what to ask when a company claims its ore body suits bioleaching: what the bacteria actually do, where heap and stirred-tank methods diverge in cost and performance, and how the downstream solvent extraction and electrowinning chain turns dissolved metal into a saleable product. The aim is evaluative competence, not general awareness.

The bacterial engine: how microbes turn sulphide rock into dissolved metal

The chemical problem is simple to state. Valuable metals like copper and gold are locked inside sulphide mineral matrices, and getting them out normally requires either a smelter or a high-pressure oxidation vessel. Bioleaching solves that problem biologically instead.

The bacteria do not dissolve the metal directly. They oxidise the sulphide matrix that traps the metal, which releases it into solution as a dissolved ionic species that can then be recovered downstream.

Two species dominate commercially: Acidithiobacillus ferrooxidans and Acidithiobacillus thiooxidans. Both are chemolithotrophs, meaning they draw their energy from inorganic oxidation reactions rather than from organic matter or sunlight. They feed on the rock itself.

Two oxidation pathways run at the same time:

1. Direct oxidation: bacteria attach to the mineral surface and oxidise it through direct contact.
2. Indirect oxidation: ferric iron in solution acts as the oxidant, and the bacteria continuously regenerate that ferric iron by oxidising ferrous iron, functioning as a catalytic loop that never runs dry.

The system also feeds itself in a second way. When the bacteria oxidise sulphur compounds, they produce sulphuric acid as a byproduct, which lowers the pH and accelerates further mineral dissolution, sustaining the very acidic environment the bacteria require.

The bacterial engine described here sits within a broader commercial landscape where bioleaching technology has expanded beyond copper and gold into a wider set of sulphidic mineral types, with engineering advances in aeration, inoculum design, and heap geometry steadily closing the gap between laboratory performance and project-scale results.

Key operating parameter Effective bioleaching typically runs at a pH of approximately 1.5 to 2.5. This is one of the first figures to look for in a project’s technical reports.

Temperature matters just as much. Mesophilic strains work best at roughly 30 to 40 degrees Celsius, while thermophilic strains push reaction rates faster at 45 to 80 degrees Celsius. The primary sulphide substrates the bacteria attack are pyrite, chalcopyrite, and arsenopyrite.

Here is what that self-reinforcing cycle means for you as an investor. Once conditions are established, the system is largely self-sustaining, which is its great advantage. But it is also brittle: disrupt any single variable, temperature, oxygen, or pH, and the microbial population can collapse and stall the entire leach.

A company that does not demonstrate active culture management in its technical disclosures is exposing you to a risk that feasibility models routinely understate.

What actually happens inside a bioleach heap

Picture yourself standing at the heap pad. Crushed ore is stacked into large piles on lined pads, and acidic solution is distributed across the top through drip lines or sprinklers. The solution trickles down through the ore, and the bacteria go to work as it goes.

The physical inputs a heap requires are straightforward but non-negotiable:

• A lined pad to contain the acidic solution and prevent it reaching groundwater
• An irrigation system (drip or sprinkler) to distribute leach solution across the surface
• Aeration pipes installed within the heap, because oxygen cannot be assumed to diffuse adequately through the ore mass on its own
• A collection pond at the base to capture the metal-laden solution

That metal-laden solution draining from the base is the pregnant leach solution (PLS), and it is routed onward to the recovery circuit.

Heap design carries one central tension. A finer crush size exposes more mineral surface for the bacteria to attack, which lifts recovery, but finer crushing costs more and risks compacting the heap so tightly that solution can no longer flow through it. Getting that balance wrong quietly undermines the whole operation.

The performance data shows why heaps look attractive on paper. In engineered heap simulations of low-grade copper ore, column tests recorded recoveries of 72% and 62% over 80 days with bacterial inoculation, against just 47% and 39% without it. The bacteria are clearly doing the heavy lifting. Note that these are simulation-scale figures, not commercial production data.

At project scale, McEwen Copper reported that Phase 1 column testwork on its Los Azules copper project in Argentina supports an average total copper recovery of 76.0% over approximately 230 days, ahead of the prior preliminary economic assessment assumption of 72.8%. These are project testwork figures rather than confirmed commercial production.

That gap between column tests and real heaps is where most heap projects disappoint investors. Column tests cannot replicate the channeling, heat loss, and uneven oxygen distribution that routinely drag real-heap recoveries below the modelled numbers.

The chalcopyrite problem: when heap bioleaching hits its limits

Heap bioleaching has a proven track record on secondary copper sulphides such as chalcocite and covellite, which respond readily to bacterial oxidation. Primary chalcopyrite is a different story.

The obstacle is passivation. A surface layer forms on chalcopyrite particles that blocks further bacterial access, effectively sealing the mineral and stalling the leach before meaningful recovery occurs. Slow kinetics and jarosite formation compound the problem.

A counterweight to optimistic projections A 2024 study of marginal chalcopyrite ores from the Brazilian Amazon achieved only 1 to 4% copper extraction after 47 days, illustrating just how severe the passivation problem can be.

The leading candidate solution is thermophilic: running heap temperatures of 45 to 78 degrees Celsius using heat-loving bacterial consortia to prevent passivation. Commercial trials have been reported in the Middle East and Chile, though these remain unverified and the approach has not been proven at full commercial scale.

For you, this is a clear red flag to watch. A project proposing heap bioleaching on a predominantly chalcopyrite ore body, without metallurgical testwork specifically addressing passivation, deserves close scrutiny. That single mineralogical distinction, secondary sulphide versus primary chalcopyrite, largely determines whether published recovery projections have historical precedent behind them or represent a method still hunting for commercial proof.

Rio Tinto’s Nuton programme represents one of the most significant industry-scale efforts to develop chalcopyrite passivation solutions, combining proprietary bacterial consortia with engineered heap environments specifically designed to maintain the elevated temperatures that prevent the surface-blocking effect that has historically limited primary copper recoveries.

Stirred-tank bioleaching: faster, more controlled, and more expensive

Where the heap runs slow and open to the elements, stirred-tank bioleaching answers those limitations directly. Ground ore concentrate is mixed with acidic bacterial culture inside enclosed reactor vessels, and continuous agitation keeps bacteria, mineral particles, and oxygen in constant contact.

The enclosure is the whole point. Inside a sealed reactor, operators can precisely control temperature, pH, oxygen, and nutrient supply, which drives faster and more consistent oxidation than any open heap can manage.

That control does not come free. Sulphide oxidation is exothermic, and excess heat can kill the microbial population, so active cooling becomes both a capital and an operating cost line.

The primary application is pre-treating refractory gold ore, where gold sits locked inside sulphide minerals that cyanidation alone cannot reach. After biological pre-oxidation cracks open the sulphides, the slurry feeds into conventional carbon-in-leach or carbon-in-pulp circuits.

The most widely referenced commercial implementation is BIOX, developed in South Africa. The Fairview plant in Barberton has operated since 1986 with a concentrate capacity of 62 tonnes per day (a historical figure from pre-2014 documentation), giving stirred-tank bioleaching a long commercial track record. BIOX documentation has historically reported gold recoveries above 90% in continuous stirred-tank circuits.

More recent laboratory work echoes the method’s speed. A 2026 bioreactor study achieved copper recovery of 86.9% over just 20 days using an optimised inoculum load.

The capital premium only makes economic sense under specific conditions: when the ore grade is high enough, the metal price strong enough, or the ore so refractory that cheaper alternatives cannot achieve acceptable recovery at all.

For you, spotting stirred-tank bioleaching in a flowsheet is itself a signal. It tells you the ore body is probably refractory, that the company has accepted higher upfront capital in exchange for faster throughput and higher recovery, and that the economics rest on a narrower set of price and grade assumptions than a heap project would.

From leach solution to refined metal: how SX-EW turns dissolved copper into cathode

Recovering the copper you have dissolved is a separate job, and it is where a project’s revenue is actually made. The pregnant leach solution arrives at the collection pond carrying dissolved copper alongside acid, dissolved iron, and other impurities. Two further stages isolate pure metal from that mixture.

1. Leach solution collection. The PLS is gathered from the base of the heap and pumped to the recovery plant. At this stage it is a contaminated, dilute solution, valuable but nowhere near saleable.
2. Solvent extraction (SX). The PLS is contacted with an organic solvent that selectively captures copper ions while leaving impurities behind in the aqueous phase. The copper-loaded organic phase is then stripped with a high-acid solution, which pulls the copper out into a clean, concentrated electrolyte ready for the final step.
3. Electrowinning (EW). An electrical current is passed through the purified electrolyte, driving copper to deposit onto cathode plates in electrolytic cells. The harvested cathode copper typically meets London Metal Exchange (LME) Grade A specifications.

Solvent extraction electrowinning has advanced significantly in reagent selectivity and cell design since the process was first commercialised at scale, with modern installations achieving copper current efficiencies above 95% and substantially lower energy consumption per tonne of cathode produced than earlier generation circuits.

Production quality benchmark LME Grade A is the output standard to expect in a copper project’s disclosures. If a project cannot reference it, ask why.

There is a loop worth noting. The depleted raffinate left over from solvent extraction is recycled back to the heap, creating a closed-loop water circuit. That is both an economic advantage, through lower reagent and water consumption, and a regulatory requirement in most jurisdictions.

Iron management runs through this whole stage. Dissolved iron must be controlled to prevent it interfering with extraction selectivity and inflating reagent consumption; let it run high, and both recovery and cost suffer.

Here is the point most investors miss. If you focus only on bacterial recovery rates and ignore the efficiency of the SX-EW plant, you are reading only the front half of the value chain. A high-recovery heap feeding an undersized or poorly configured SX-EW circuit will still produce a sub-economic project, and any disclosure that reports leach recovery without SX-EW recovery is showing you an incomplete picture.

Reading bioleaching claims in company reports: what the economics actually tell you

Now to turn all of this into an evaluation frame. The economics of the two methods diverge sharply, and knowing where the money goes tells you what to interrogate.

Heap capital is dominated by earthworks, liner installation, and pond construction, with operating costs driven by solution pumping, aeration, and reagent consumption. Stirred-tank capital goes into engineered reactor vessels and control systems, with operating costs driven by the energy needed for agitation and temperature control. The two are not interchangeable, and neither is inherently cheaper across a project’s life.

Heaps carry a specific timeline risk. Because cycle times stretch to months or years, capital sits tied up far longer before revenue arrives, and extrapolating bench-scale or column performance to a full-scale heap routinely understates the real recovery timeline.

Sensitivity to active management is easy to underestimate. Designed microbial consortia have been shown to increase copper recoveries by up to 32% compared with abiotic controls, which tells you how much outcome depends on population management rather than geology alone.

Environmental exposure is a viability issue, not a footnote. A 2026 review flagged treated bioleach materials containing copper at levels between 27.3 and 3,323 mg/kg against EU regulatory thresholds of 1,000 to 1,750 mg/kg, illustrating the potential scale of contamination if containment fails (these figures are unverified). Acid rock drainage, containment failure, and water balance all feed directly into permitting, operating costs, closure liabilities, and social licence.

The EU Extractive Waste Directive sets binding requirements for how mining operations must prevent acid drainage and control leachate from sulphidic waste, establishing the regulatory baseline that bioleach projects operating in or exporting to European markets must satisfy.

One structural limitation is worth naming plainly: specific CAPEX ranges distinguishing heap from stirred-tank bioleaching are not available in accessible post-2024 literature. You cannot lean on published industry benchmarks. You have to interrogate project-specific disclosures instead.

Five questions to ask before accepting a bioleaching recovery estimate

Use these as a working checklist. If a company’s technical disclosure cannot answer one of them clearly, that gap warrants a follow-up question to management or an independent technical review.

• Has the ore mineralogy been confirmed, and does the chosen method match it? Secondary sulphide or primary chalcopyrite changes everything.
• What scale is the testwork behind the recovery estimate: bench, column, pilot, or commercial? Column results extrapolated to a full heap are the most common source of disappointment.
• Is SX-EW recovery reported separately from leach recovery, so you can see the full chain rather than just the upstream number?
• Is bacterial culture management described, showing the company understands how sensitive recovery is to the microbial population?
• Does the environmental management plan address acid rock drainage and water balance in concrete terms?

When strong column recoveries appear without the ore mineralogy, the scale-up methodology, or the SX-EW configuration attached, those omissions are as informative as the numbers themselves. An investor who cannot spot what is missing is at a structural disadvantage.

This article is for informational purposes only and should not be considered financial advice. Investors should conduct their own research and consult with financial professionals before making investment decisions.

What a rigorous bioleach project looks like, and what that means for evaluation

Strip everything back and one question outranks the rest: was the method chosen because the metallurgy justifies it, or because it minimises the capital the company has to disclose? That distinction is the single most important test in evaluating a bioleach project.

Bioleaching is a proven, commercially established technology for the right ore types at the right scale. The BIOX track record since 1986 and the extensive copper heap operations running globally confirm that. But the commercial proof set does not extend to every ore type equally.

Bacterial metal recovery at industrial scale requires more than getting the chemistry right in a laboratory; the Sudbury biomining cluster illustrates how co-located infrastructure, shared microbial expertise, and proximity to sulphidic ore bodies have combined to make consistent commercial-scale operation viable in a way that isolated projects have struggled to replicate.

The chalcopyrite gap is the benchmark for what “not yet proven at scale” looks like, just as the BIOX record is the benchmark for what “proven” looks like. A project sitting on either side of that line should be read very differently.

Your job is to read the technical evidence, not the marketing narrative. A recovery percentage means little without the ore type, the scale context, and the downstream configuration standing behind it.

Bioleaching is neither a shortcut to cheap processing nor an exotic fringe method. It works reliably in specific conditions and fails predictably outside them. The investor’s task is to determine which set of conditions a given project actually describes.

With no standardised public CAPEX benchmarks to fall back on, project-specific due diligence cannot be shortcut by reference to industry averages. Get the full chain right, from bacterial oxidation through SX-EW to the evaluation checklist, and you can tell genuine technical grounding from a capital-minimisation story. That distinction is where capital allocation quality is won or lost.